Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
AN2 Therapeutics, Inc. - Common Stock
(NQ:
ANTX
)
1.180
+0.010 (+0.85%)
Streaming Delayed Price
Updated: 11:18 AM EST, Dec 16, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about AN2 Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
Next >
Why Is AN2 Therapeutics (ANTX) Stock Down 35% Today?
↗
August 09, 2024
AN2 Therapeutics stock is down on Friday after ANTX investors learned of the company terminating its EBO-301 Phase 2/3 clinical trial.
Via
InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
↗
August 09, 2024
We have all of the biggest pre-market stock movers that traders need to know about on Friday with the latest news breakdowns!
Via
InvestorPlace
AN2 Therapeutics Provides Update on EBO-301 Phase 2/3 Study Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium Complex (MAC) Lung Disease
August 08, 2024
From
AN2 Therapeutics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
↗
June 14, 2024
Via
Benzinga
ANTX Stock Earnings: AN2 Therapeutics Beats EPS for Q1 2024
↗
May 14, 2024
ANTX stock results show that AN2 Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
AN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific Highlights
May 14, 2024
From
AN2 Therapeutics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
↗
April 04, 2024
Via
Benzinga
ANTX Stock Earnings: AN2 Therapeutics Beats EPS for Q4 2023
↗
March 28, 2024
ANTX stock results show that AN2 Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights
March 28, 2024
From
AN2 Therapeutics, Inc.
Via
Business Wire
ZoomInfo Technologies To Rally Around 50%? Here Are 10 Top Analyst Forecasts For Tuesday
↗
February 13, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Nasdaq Edges Lower; ContextLogic Shares Surge
↗
February 12, 2024
U.S. stocks traded mostly higher toward the end of trading, while the Nasdaq Composite moved slightly lower on Monday. The Dow traded up 0.52% to 38,873.28 while the NASDAQ fell 0.10% to 15,975.16. The...
Via
Benzinga
Topics
Stocks
12 Health Care Stocks Moving In Monday's Intraday Session
↗
February 12, 2024
Via
Benzinga
Dow Surges Over 150 Points; Gilead Sciences To Acquire CymaBay Therapeutics For $4.3B
↗
February 12, 2024
U.S. stocks traded higher midway through trading, with the Dow Jones index jumping over 150 points on Monday. The Dow traded up 0.48% to 38,856.99 while the NASDAQ rose 0.26% to 16,031.87. The S&P 500...
Via
Benzinga
Topics
Stocks
Why Big Lots Shares Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Monday's Mid-Day Session
↗
February 12, 2024
Shares of Big Lots, Inc. (NYSE: BIG) fell sharply during Monday’s session after the company reported preliminary fourth-quarter results. Also, Loop Capital downgraded the stock from Hold to Sell and...
Via
Benzinga
US Stocks Mixed; Trimble Issues Weak Outlook
↗
February 12, 2024
U.S. stocks traded mixed this morning, with the Dow Jones index falling around 20 points on Monday. Following the market opening Monday, the Dow traded down 0.05% to 38,651.80 while the NASDAQ rose...
Via
Benzinga
Topics
Stocks
Why Is Infectious Disease-Focused AN2 Therapeutics Stock Sinking Today?
↗
February 12, 2024
AN2 Therapeutics pauses Phase 3 enrollment for epetraborole trial in Mycobacterium Avium Complex lung disease. Updates expected in summer 2024.
Via
Benzinga
Monday.com Reports Q4 Results, Joins AN2 TherapeuticsAnd Other Big Stocks Moving Lower In Monday's Pre-Market Session
↗
February 12, 2024
U.S. stock futures were mixed this morning, with the Dow futures trading lower by around 45 points on Monday. Shares of monday.com Ltd. (NASDAQ: MNDY) fell sharply in today’s pre-market trading after...
Via
Benzinga
Topics
Stocks
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
February 12, 2024
Via
Benzinga
AN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Disease
February 12, 2024
From
AN2 Therapeutics, Inc.
Via
Business Wire
AN2 Therapeutics to Present at Oppenheimer Healthcare Life Sciences Conference
January 30, 2024
From
AN2 Therapeutics, Inc.
Via
Business Wire
AN2 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business and Scientific Highlights
November 09, 2023
From
AN2 Therapeutics, Inc.
Via
Business Wire
AN2 Therapeutics to Present at Upcoming Investor Conferences
November 06, 2023
From
AN2 Therapeutics, Inc.
Via
Business Wire
AN2 Therapeutics Signs License Agreement with the University of Georgia Research Foundation to Develop Novel Boron-Based Therapy for Chagas Disease
October 18, 2023
From
AN2 Therapeutics, Inc.
Via
Business Wire
AN2 Therapeutics to Present New Data for Epetraborole at IDWeek 2023
October 11, 2023
From
AN2 Therapeutics, Inc.
Via
Business Wire
AN2 Therapeutics Signs Grant Agreement to Discover Novel, Boron Based Therapies for Tuberculosis and Malaria
September 26, 2023
From
AN2 Therapeutics, Inc.
Via
Business Wire
AN2 Therapeutics commences Phase 3 Part of Phase 2/3 Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium complex (MAC) Lung Disease
September 13, 2023
From
AN2 Therapeutics, Inc.
Via
Business Wire
Top 5 Health Care Stocks That May Fall Off A Cliff
↗
September 06, 2023
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.
Via
Benzinga
$16M Bet On This Biotechnology Stock? Check Out These 3 Stocks Insiders Are Buying
↗
August 23, 2023
Although U.S. stocks closed mostly lower on Tuesday, there were a few notable insider trades.
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
↗
August 17, 2023
Via
Benzinga
AN2 Therapeutics Announces Pricing of $70.0 Million Underwritten Offering of Common Stock
August 15, 2023
From
AN2 Therapeutics, Inc.
Via
Business Wire
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today